SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
SKYE

Skye Bioscience, Inc. (NASDAQ:SKYE)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.70-$0.09 (-11.03%)
 
Market cap
$3.10M
Insider Score
Health Score
Analyst consensus
Listed since
Jan 6, 2015
Market Cap$3.10M-93.3%
Revenue (ttm)$0
Net Income-$37.67M+26.5%
EPS-$7.59+25.9%
Shares Out4.42M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume283,761
Open$0.80
Previous Close$0.79
Day's Range$0.49 - $0.80
52-Week Range$0.48 - $11.04
Beta3.15
AnalystsBuy
Price Target$12.00(+1614.29%)
Earnings DateMar 9, 2027

About SKYE

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

Address
11250 El Camino Real, San Diego, CA, 92130, US
Market Cap
3 million
Employees
12
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$889.20K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From SKYE’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-11.03%
5 Days
-36.94%
1 Month
-56.79%
6 Months
-89.44%
1 Year
-93.27%

$SKYE stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in SKYE holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by SKYE's directors and management

Net Shares Purchased by Insiders−2M−1M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

SKYE Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New SKYE patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to SKYE from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in SKYE

VXFVanguard Extended Market ETF$29.60K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from SKYE’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
30
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-48.0 since Aug 21
0255075100Aug 21 — Insider Score 48.0Aug 22 — Insider Score 48.0Aug 23 — Insider Score 48.0Aug 24 — Insider Score 48.0Aug 25 — Insider Score 48.0Aug 26 — Insider Score 48.0Aug 27 — Insider Score 48.0Aug 28 — Insider Score 48.0Aug 29 — Insider Score 48.0Aug 30 — Insider Score 48.0Aug 31 — Insider Score 48.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 23.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.